In August 2001, I told a US Senate subcommittee that as much as half of stem cell revenue would likely end up going to patent holders because of absurd patents on the human embryo. No one seemed to care. The debate over embryonic stem cells then was whether it was ethical to do research on them.
Office of Strategic Communication